ico-007
Nucleic acidexperimental
Clinical trial activity
2 trials · 21 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00886808)
Timeline
Indications
Studied for
Mechanism of action
- RAF proto-oncogene serine/threonine-protein kinaseANTISENSE INHIBITOR
RAF1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ico-007
- ico-007
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01565148 | Phase 2 | Feb 1, 2012 | Austin Retina Associates, Black Hills Regional Eye Institute, East Bay Retina Institute, Elman Retina Group, Florida Retina Institute, Gulf Coast Eye Institute, Icahn School of Medicine at Mount Sinai, iCo Therapeutics Inc., Johns Hopkins University, Juvenile Diabetes Research Foundation, Retina Consultants Houston, Retina Consultants of Hawaii, Retina Group of Florida, Retina Institute of Hawaii, Retinal Consultants of Arizona, Retina Macula Institute, Spokane Eye Clinic, Texas Retina Associates in Arlington, Texas Retina Associates in Dallas, University of Nebraska, Vitreo-Retinal Associates, Michigan |
| NCT00886808 | Phase 1 | Feb 1, 2008 | iCo Therapeutics Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (21)
21 organizations
Page 1 / 2